The Risk of Fatal Arrhythmias Associated With Sertraline in Patients With Post-myocardial Infarction Depression.
cardiovascular disease
depression
life threatening arrhythmia
mental health illness
post-myocardial infarction
sertraline
ventricular tachycardia (vt)
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
09
08
2022
accepted:
08
09
2022
entrez:
14
10
2022
pubmed:
15
10
2022
medline:
15
10
2022
Statut:
epublish
Résumé
Sertraline is a first-line antidepressant and the most commonly used in the treatment of selective serotonin reuptake inhibitor (SSRI) in major depression. It is preferred due to its central and peripheral actions on the serotonergic system in patients with mental health issues as well as cardiovascular disease, particularly post-myocardial infarction depression. Some of the feared adverse effects include QT prolongation, arrhythmias including Torsades de pointed, and sudden cardiac death, which are associated with older antidepressants and are rarely seen with SSRIs, including sertraline. We tried to understand the risks associated with sertraline use in cardiac patients. We reviewed all the relevant information from inception up to July 2022 regarding the risks of sertraline use in cardiovascular diseases, particularly with a focus on post-myocardial infarction depression, and gathered around 500 articles in our research and narrowed it down to 37 relevant articles. The database used was PubMed and the keywords used are sertraline, arrhythmia, major depression, post-myocardial infarction, and ventricular tachycardia. We carefully screened all relevant articles and found articles supporting and refuting the effects of sertraline in increasing cardiovascular morbidity and mortality. We concluded that there is a significant variability due to confounding factors affecting individual cases. Overall, sertraline has no increased risk in comparison with other antidepressants and a comparatively preferable safety profile to other SSRIs like citalopram in general cases. Any patient with a high risk of arrhythmias due to any etiology should receive a screening ECG before sertraline prescription for baseline QT interval and genotyping for any serotonin transporter/receptor variations. Patients should also be periodically monitored for drug-drug interactions while on therapy. We encourage further research, including randomized clinical trials and post-marketing surveillance regarding the use of sertraline in high-risk cases.
Identifiants
pubmed: 36237772
doi: 10.7759/cureus.28946
pmc: PMC9547663
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e28946Informations de copyright
Copyright © 2022, Gutlapalli et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Psychiatry (Edgmont). 2009 Jan;6(1):38-51
pubmed: 19724742
Cochrane Database Syst Rev. 2010 Apr 14;(4):CD006117
pubmed: 20393946
J Cardiovasc Nurs. 2008 Nov-Dec;23(6):489-96
pubmed: 18953212
Dialogues Clin Neurosci. 2002 Mar;4(1):47-56
pubmed: 22034133
Psychother Psychosom. 2018;87(2):85-94
pubmed: 29533962
CNS Drug Rev. 2001 Spring;7(1):1-24
pubmed: 11420570
Chin Med J (Engl). 2021 Nov 10;134(22):2656-2665
pubmed: 34759230
Harv Rev Psychiatry. 2018 Jul/Aug;26(4):175-184
pubmed: 29975336
J Affect Disord. 2009 Dec;119(1-3):132-41
pubmed: 19375170
Aust N Z J Psychiatry. 2011 Sep;45(9):712-25
pubmed: 21888608
Neuropsychiatr Dis Treat. 2019 May 17;15:1287-1310
pubmed: 31190834
Front Psychiatry. 2022 Mar 16;13:831359
pubmed: 35370809
J Tehran Heart Cent. 2013 Oct 28;8(4):169-76
pubmed: 26005484
JAMA. 2009 Oct 21;302(15):1651-7
pubmed: 19843899
Postgrad Med J. 2005 Jan;81(951):33-40
pubmed: 15640426
Clin Geriatr Med. 2014 Aug;30(3):517-34
pubmed: 25037293
Ger Med Sci. 2014 May 07;12:Doc09
pubmed: 24808816
Prog Cardiovasc Dis. 2013 May-Jun;55(6):582-9
pubmed: 23621968
J Exp Pharmacol. 2019 Dec 23;11:149-158
pubmed: 31920405
Neurol Int. 2021 Aug 05;13(3):387-401
pubmed: 34449705
BMJ. 2016 Mar 22;352:i1350
pubmed: 27005565
Neurosci Biobehav Rev. 2017 Mar;74(Pt B):433-443
pubmed: 27590831
Mater Sociomed. 2019 Jun;31(2):110-114
pubmed: 31452635
J Am Coll Cardiol. 2010 Aug 24;56(9):692-9
pubmed: 20723799
Expert Opin Pharmacother. 2011 Jan;12(1):85-98
pubmed: 20715885
CNS Drugs. 2020 Nov;34(11):1133-1147
pubmed: 33064291
J Am Heart Assoc. 2020 Nov 17;9(22):e018686
pubmed: 33164638
Iran J Psychiatry. 2017 Jul;12(3):206-213
pubmed: 29062373
Front Pharmacol. 2012 May 10;3:76
pubmed: 22590457
J Clin Psychiatry. 2019 Jun 4;80(4):
pubmed: 31163106
Prim Care Companion CNS Disord. 2013;15(4):
pubmed: 24392265
Med Sci Monit. 2011 Sep;17(9):RA205-14
pubmed: 21873959
Am Heart J. 2008 Sep;156(3):437-44
pubmed: 18760123
Clin Cardiol. 1997 Mar;20(3):196-200
pubmed: 9068903
Neuropsychiatr Dis Treat. 2010 May 06;6:123-36
pubmed: 20505844
BMC Psychiatry. 2017 Feb 8;17(1):58
pubmed: 28178949